Oncolytics Biotech Inc. - Product Pipeline Review - Q4 2010

Oncolytics Biotech Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Oncolytics Biotech Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oncolytics Biotech Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oncolytics Biotech Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oncolytics Biotech Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oncolytics Biotech Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oncolytics Biotech Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oncolytics Biotech Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oncolytics Biotech Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oncolytics Biotech Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oncolytics Biotech Inc. and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
Oncolytics Biotech Inc. Snapshot
Oncolytics Biotech Inc. Overview
Key Information
Key Facts
Oncolytics Biotech Inc. – Research and Development Overview
Key Therapeutic Areas
Oncolytics Biotech Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Oncolytics Biotech Inc. – Pipeline Products Glance
Oncolytics Biotech Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Oncolytics Biotech Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Oncolytics Biotech Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Oncolytics Biotech Inc. – Drug Profiles
Reolysin + Paclitaxel + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Reolysin
Product Description
Mechanism of Action
R&D Progress
REOLYSIN + Gemzar
Product Description
Mechanism of Action
R&D Progress
REOLYSIN + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Reolysin + Paclitaxel + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Reolsyin + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Reolysin
Product Description
Mechanism of Action
R&D Progress
Reolysin + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
REOLYSIN + FOLFIRI
Product Description
Mechanism of Action
R&D Progress
Reolysin + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Oncolytics Biotech Inc. – Pipeline Analysis
Oncolytics Biotech Inc. – Pipeline Products by Therapeutic Class
Oncolytics Biotech Inc. Pipeline Products By Target
Oncolytics Biotech Inc. – Pipeline Products by Molecule Type
Oncolytics Biotech Inc. – Company Statement
Oncolytics Biotech Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group
Jun 07, 2010: Oncolytics Collaborators Present Positive Updated UK Phase I/II Trial Results In Advanced Solid Cancers At ASCO Annual Meeting
Jun 07, 2010: Oncolytics Collaborators Present Positive Updated UK Phase I/II Trial Results In Advanced Solid Cancers At ASCO Annual Meeting
Jun 01, 2010: Oncolytics Receives Approval From Belgium FAMHP To Conduct Phase III Trial For REOLYSIN In Head And Neck Cancers
May 26, 2010: Oncolytics Biotech Initiates Enrolment In US Phase II Pancreatic Cancer Clinical Trial
May 25, 2010: Oncolytics Biotech Opens Enrollment In Phase III Trial For REOLYSIN In Head And Neck Cancers
May 21, 2010: Oncolytics Biotech Announces Reovirus Research To Be Presented At ASCO Annual Meeting
Financial Deals Landscape
Oncolytics Biotech Inc., Deals Volume Summary, 2004 to YTD 2010
Oncolytics Biotech Inc., Deals Summary By Region, 2004 to YTD 2010
Oncolytics Biotech Inc., Deals Summary, 2004 to YTD 2010
Oncolytics Biotech Inc. Detailed Deal Summary
Acquisition
Oncolytics Acquires 10% Stake In British Canadian Biosciences
Equity Offering
Oncolytics Biotech Announces Exercise Of Underwriter's Allotment Option
Oncolytics Biotech Completes Public Offering Of $6 Million
Oncolytics Biotech Completes Public Offering Of $3 Million
Oncolytics Biotech Completes Public Offering Of $12 Million
Oncolytics Biotech Completes Private Placement Of $16 Million
Oncolytics Biotech Completes Private Placement Of $8.28 Million
Oncolytics Biotech Completes Private Placement Of $5 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer